BaconLover
Founding Member
Half a million shares were shorteD yesterday
BRN Discussion Ongoing
- Thread starter TechGirl
- Start date
Half a million shares were shorteD yesterday
Tony Coles
Regular
To the 1000 eyes of BRN share holders, are we ever going to run out of these so called dots.......... joiningThey even got a link with photos of each companies representative. No dots required.
it amazes me the research you guys and gals do, well done and thank god for the stock exchange, what a blessing to read in this forum, thanks again! BRN will change lives and families. 
Bravo
If ARM was an arm, BRN would be its biceps๐ช!
1. Pitt street Research 20 August 2021
Notably, BRN is one of the few players in the market, along with Prophesee and Nepes Corp (General Vision Inc.), that already have products
targeting this segment, which we believe provides it an early mover advantage. However, neither Prophesee nor Nepes have on-chip convolution,
while both have only very low numbers of neurons.
2. Prophesee's CEO explains the future of sensors that only see changes - 12 Oct 2021
spectrum.ieee.org
3.
Notably, BRN is one of the few players in the market, along with Prophesee and Nepes Corp (General Vision Inc.), that already have products
targeting this segment, which we believe provides it an early mover advantage. However, neither Prophesee nor Nepes have on-chip convolution,
while both have only very low numbers of neurons.
2. Prophesee's CEO explains the future of sensors that only see changes - 12 Oct 2021
Event-Based Camera Chips Are Here, Whatโs Next?
Prophesee's CEO explains the future of sensors that only see changes
spectrum.ieee.org
3.
Rskiff
Regular
I remember the days when it moved .1 of a cent!! Happy times now and well worth the wait. Also willing to wait longer as only the beginning. Exciting times ahead, well done to the Brainchip team bringing this technology to market.Remember the days when the share price would move 1 or 2 cents. Now it's like 10 cents pah! Everyday.
buena suerte :-)
BOB Bank of Brainchip
DJM263
LTH - 2015
Hey @stockduckyes, but it seems to me that its not. Sorry for making you all nervous.
It doesn`t looks like a chip, right?
If it is or isn't you are having a go and that's all that matters when your a student in the 1000 Eyes classroom.
Well done, and Danke schรถn
Deena
Regular
Thanks simoni
Makeme 2020
Regular
A good Hangover cure is MORE BEER.................LOL....................$$$$$$$$$$$$$$$
LOLHave another one .... Hehir of the dog ...
DJM263
LTH - 2015
I'm gunna guess @Fact Finder all your followers are now tuned in and by the way you now have over 800 more!
MaxwellAnne
Regular
Very interesting read thanks for sharing MDfollowing on from that this is an interesting read accepting that edge is the future distruptive market with edge expected to reach over 250 billion dollars by 2024
Cloud & Edge โฆ it takes two to tango
Cloud & Edge โฆ it takes two to tangoMilind Dikshit2021-07-06 This article was originally published in Express Computer and has been reproduced herewww.capgemini.com
curlednoodles
Regular
Perhaps their employers have had a stern conversation with them about the importance of being balanced to not reveal your true intentions/motives.
Fox151
Regular
Or their sponsors don't want to sponsor a page where the only voices are negative downrampers.
TheFunkMachine
seeds have the potential to become trees.
Hi Brainchippers, so I have been in discussions with Samuel from Biotome regards to the private capital Raising and I have just got conformation that I can share this email with you guys. I think there is some valuable information here to be looked at.
If you have been following this process on the Biotome thread you are aware that he told me to keep our conversation private, but it turns out he was only referring to information specifically relating to the cap raise and not the serious of questions/answers relating to their Brainchip partnership. I have attached the confirmation email below and copy/pasted the response that has valuable information.
Hi Petter,
Thanks for getting back and showing interest.
Iโd be happy to respond as detailed as I can (keeping in mind confidentiality as you alluded to).
It is still early days when it comes to research results from the collaboration. In very general terms, we have seen that Akida can be used to process the type of data we provide, and can efficiently recognise patterns in our datasets. Our joint project involves a great deal of logistics with regards to getting hold of suitable patient samples. And as always in the type of work we are involved in, getting hold of patient samples (and ethics approvals etc) is usually what takes up the majority of the project time.
Whenever we have sent data to the Brainchip team, they have been very quick to process and get it back to us.
We donโt expect to be able to report any final findings from our project before June this year.
We are definitely positive with regards to using the Akida chip in future products. But it is early days, and we cannot say for sure whether this will happen or not. Where Akida can provide most value is with a multiplex (many markers tested in parallel) point-of-care test. We could then envisage the Akida chip being embedded in a hand-held device (similar to a finger-prick glucose test device), and would carry out in-device data processing and recognition. Such a test/device is however a few years away for us, and would need substantial capital raising to reach.
In our best case scenario, we aim to have a stomach cancer risk test on the US market within 18 months. The path to market is long with regards to FDA approvals. Typically, diagnostic companies would aim to first market a research-use-only test. Such a test would not require FDA approval, so it has a shorter path to market, would still generate revenue and would importantly be a good marketing tool for when the test is FDA-approved and can be used clinically. To reach FDA approval is likely to take an additional 15-18 months.
The customers will be different, depending how you view the question:
- The customers we will sell to are likely one major diagnostic company partner per product. Our aim is to license or sell the IP for each of our projects/products to one partner that can market the diagnostic globally. We would receive royalties on sales.
- The end user of our diagnostic products (marketed to by the licensee of our IP) would be pharmacies / GPs that carry out testing for stomach cancer risk / pre-eclampsia risk / SARS-CoV-2 antibodies, or in some cases (if regulatory approval can be received) individuals purchasing the diagnostic test on their own accord before consulting a GP/specialist about the results.
- For a Research-use-only test, the end customer would for example be a clinician specialist (gastroenterologist etc) that would use our stomach cancer risk test in their clinical research studies.
Since the deadline is very fast approaching, Iโm also sending you two docs that explains the process, as well as the more detailed company information. Should you decide to go further, please let me know and I will send the remaining forms that are mentioned in the first document. Please note that the deadline for giving an investment decision is tomorrow (AWST).
Best regards,
Samuel
If you have been following this process on the Biotome thread you are aware that he told me to keep our conversation private, but it turns out he was only referring to information specifically relating to the cap raise and not the serious of questions/answers relating to their Brainchip partnership. I have attached the confirmation email below and copy/pasted the response that has valuable information.
Hi Petter,
Thanks for getting back and showing interest.
Iโd be happy to respond as detailed as I can (keeping in mind confidentiality as you alluded to).
It is still early days when it comes to research results from the collaboration. In very general terms, we have seen that Akida can be used to process the type of data we provide, and can efficiently recognise patterns in our datasets. Our joint project involves a great deal of logistics with regards to getting hold of suitable patient samples. And as always in the type of work we are involved in, getting hold of patient samples (and ethics approvals etc) is usually what takes up the majority of the project time.
Whenever we have sent data to the Brainchip team, they have been very quick to process and get it back to us.
We donโt expect to be able to report any final findings from our project before June this year.
We are definitely positive with regards to using the Akida chip in future products. But it is early days, and we cannot say for sure whether this will happen or not. Where Akida can provide most value is with a multiplex (many markers tested in parallel) point-of-care test. We could then envisage the Akida chip being embedded in a hand-held device (similar to a finger-prick glucose test device), and would carry out in-device data processing and recognition. Such a test/device is however a few years away for us, and would need substantial capital raising to reach.
In our best case scenario, we aim to have a stomach cancer risk test on the US market within 18 months. The path to market is long with regards to FDA approvals. Typically, diagnostic companies would aim to first market a research-use-only test. Such a test would not require FDA approval, so it has a shorter path to market, would still generate revenue and would importantly be a good marketing tool for when the test is FDA-approved and can be used clinically. To reach FDA approval is likely to take an additional 15-18 months.
The customers will be different, depending how you view the question:
- The customers we will sell to are likely one major diagnostic company partner per product. Our aim is to license or sell the IP for each of our projects/products to one partner that can market the diagnostic globally. We would receive royalties on sales.
- The end user of our diagnostic products (marketed to by the licensee of our IP) would be pharmacies / GPs that carry out testing for stomach cancer risk / pre-eclampsia risk / SARS-CoV-2 antibodies, or in some cases (if regulatory approval can be received) individuals purchasing the diagnostic test on their own accord before consulting a GP/specialist about the results.
- For a Research-use-only test, the end customer would for example be a clinician specialist (gastroenterologist etc) that would use our stomach cancer risk test in their clinical research studies.
Since the deadline is very fast approaching, Iโm also sending you two docs that explains the process, as well as the more detailed company information. Should you decide to go further, please let me know and I will send the remaining forms that are mentioned in the first document. Please note that the deadline for giving an investment decision is tomorrow (AWST).
Best regards,
Samuel
MaxwellAnne
Regular
A great read thanks for posting GL. I love this succint description of akida as it sets out its advantages very clearly in just a few words:
โA low-power artificial intelligence chip that operates completely autonomously without a CPU or Internet connection.โ
Mccabe84
Regular
By curing it do you mean every cent it goes up your having a beer and when it goes down a cent youโre having a shot for the disappointment
Similar threads
